Amrit Ray, M.D.

https://lnkd.in/gKzw332q Biotechnology Big Pharmaceutical Industry: In the July 11 report, the analysts calculate that products #losing #exclusivity through 2030 are generating a combined $183.5 billion in annual sales, with #Amgen, #BristolMyersSquibb and #Merck facing the most #exposure of their revenue. Per Morgan Stanley’s metrics, #JJ is in excellent shape as just 33% of its revenue is exposed to patent expirations through 2030, compared to an industry average of 38%. Other #biopharma companies in good positions regarding their #patentcliffs are #Vertex (6%), #Gilead (24%), #AbbVie (29%), #EliLilly (31%) and #Pfizer (33%).

2

ONO PHARMACEUTICAL CO., LTD. is set to make its largest acquisition yet, purchasing Deciphera Pharmaceuticals, an American cancer drug maker, for $2.4 billion. 💼 The move comes as Ono seeks to fuel #growth with new drug candidates, especially as key patents on its Opdivo #cancer immunotherapy are set to expire in 2028. 🌱 Established in 2003, Deciphera is the maker of the Qinlock cancer drug available in the U.S. and Europe. 🩺 Qinlock boasts a unique mechanism that inhibits enzymes critical for cancer cell proliferation. 🛑 Additionally, Deciphera holds promising new drug candidates. 🌟 One such candidate, a treatment for benign tumors in joints, is in the final stages of clinical trials in #Europe and the #US, with approval slated for 2024. 💉 Deciphera is also developing a drug to address complications in blood cancer treatment. 🩸 #Japan #Pharma #Pharmaceutical https://lnkd.in/dppfbjsy

1

Illumina has forecasted a 2% to 3% decline in core segment sales for 2024 due to reduced biotech funding impacting R&D investment. Q2 2024 revenue was $1.11 billion, down 5.4% year-over-year but exceeding expectations. Sequencing product sales fell 6.6%, and sequencing instruments dropped 39.9%. Profits were lower than expected, partly due to a $1.47 billion goodwill impairment from the Grail spin-off. Click here to learn more: https://yhoo.it/3AmW6Mw #illumina #genomics #nextgenerationsequencing #venturecapital #privateequity #deerbornedifference

4

#EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the #esophagus, creating pain and difficulty with swallowing food. According to market research from Clearview, EoE affects more than 450,000 people in the United States and has been identified by the American #Gastroenterological Association as rapidly increasing in both incidence and prevalence. Impacts from both symptoms and interventions frequently lead to mental health issues, compounding the disease burden of EoE for both the healthcare system and the individual. Today, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage #biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). - Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks - The fourth cohort showed the greatest percentage change in histology (EoEHSS2) scores of any cohort to date - The RESOLVE Phase 1b/2a trial is progressing as anticipated with no serious adverse events reported in all four fully-dosed cohorts "The RESOLVE trial is progressing rapidly and we continue to observe positive data on efficacy and safety outcomes with EP-104GI, with the fifth cohort expected to read out in November 2024," said Dr. James Helliwell, Chief Executive Officer of Eupraxia. "Overall, we are encouraged by the data that we have seen across a number of key metrics and remain optimistic that we'll see further improvements in patient response as the trial progresses towards an optimal dosing level." https://lnkd.in/gVGEm_Dd

1

After restructuring and prioritization on the key products, Pfizer, Merck Beat Wall Street Expectations Amid Strong Biopharma Q2 Earnings Season - BioSpace Second-quarter revenues were better than analysts expected as Merck reported 16% growth for its blockbuster cancer treatment Keytruda, while Pfizer benefited from its ongoing cost-cutting efforts and sales of its COVID-19 antiviral Paxlovid. Merck and Pfizer announced second-quarter earnings on Tuesday, with both companies beating the Wall Street consensus, which was driven by sales of their blockbuster drugs Keytruda and the Vyndaqel family of treatments, respectively. An analyst report from the Bank of Montreal Capital Markets called it a “solid quarter” for Pfizer. Total revenue for Q2 was $13.2 billion, a 2% increase from the same period last year, beating the consensus of $12.96 billion. Pfizer has raised its year-end guidance range from $59.5 billion to $62.5 billion. Previously, Pfizer’s guidance was between $58.5 billion and $61.5 billion. Merck’s global sales were $16.1 billion, beating Guggenheim Securities’ estimate of $15.7 billion and the FactSet consensus of $15.8 billion. It has also raised its guidance and now expects its worldwide sales to be between $63.4 billion and $64.4 billion. Pfizer has been hit with revenue drops over the past few quarters, but Q2 saw strong sales of the cardiomyopathy drugs Vyndaqel, Vyndamax, and Vynmac. Sales of these drugs reached over $1.3 billion, a 71% increase from the same quarter last year, driven by market demand in the U.S. and internationally. Sales of products acquired from Seagen reached $845 million globally in Q2. By comparison, the blood clot prevention drug Eliquis brought in $1.8 billion, an 8% increase from the same quarter last year due to high demand in the U.S. and internationally. Even sales of some COVID-19 products were positive for Pfizer in Q2. The antiviral treatment Paxlovid brought in $251 million, a 79% increase from the prior year period. https://lnkd.in/eBMemmft

12

The number of biopharma M&A deals more than doubled in the first quarter of 2024 compared to the same period a year ago, exemplifying a top exit route for pre-commercial companies vying for validation and attention. 13 biopharma M&A deals in the first quarter of 2024 compared to six in the first quarter of 2023. 47 deals in the last twelve months through March 2024, compared to 42 through March 2023. #mergerandacquisition #investing #CEO #biopharma #wheretoinvest #druginnovation #artificialinyelligence

1

With one of the largest and most compelling #oncology pipelines in the industry focused on #hematology and #solidtumors, we’re just beginning to deliver on our aspiration of becoming the most impactful oncology company and improving care for patients with cancer. Learn more about the breadth of BeiGene’s pipeline in my recent interview with BiotechTV at #ASCO24.

384

6 Comments

In 2023, a record number of cell and gene therapy (CGT) products received regulatory approval in the US, and a still greater number of approvals is anticipated in 2024. Andrew Frazer and James Cody discuss the evolving C&GT landscape in European Pharmaceutical Review. https://bit.ly/4ekUUc1

55

This week, Mark Campbell, RxBenefits, Inc.'s Chief Pharmacy Officer shared his perspective on the way drug manufacturers, formulary practices by the leading pharmacy benefit managers, and the economics of rebates have led to patients, plan sponsors, and our healthcare system missing out on the significant savings #biosimilars could have delivered. Great insights and lessons we can learn for the future

10

We’re honored that Alcami and our CEO William Humphries were included in Investment Reports' new publication, 'The New Era of Life Sciences 2024'. Don’t miss this comprehensive and inspiring exploration of the advancements shaping healthcare and beyond. Download it here: https://gag.gl/mLwcJY #Alcami #CEO #InvestmentReports #LifeSciences

8

Oligos staying hot... Despite biopharma's "mud and stick" season, oligos remain a hot area. The market seemed to forget about them in the height of the pandemic in favor of mRNA and are now re-remembering they are a proven modality that generates real value for patients and revenue for their developers. https://lnkd.in/gs5piJGC With that in mind, a new RNA company out of Versant from the former team at Chinook Therapeutics trying to drug the kidney. Outside of the liver, the lung and kidney (and T-cells generally) are the areas of most interest (partially driven by delivery vehicles that can get to those organs / cells). The company also has an investment off the bat and partnership with Novartis. This shows real focus in their development plan to get to the clinic. Always important but especially now given the market and capital constraints. We have not seen the last of mega biotechs going under I'll bet. So oligos roll on... but... delivery delivery delivery. #biotech #genetherapy #drugdiscovery

223

6 Comments

We are thrilled to announce that iRegene has received US FDA IND approval for NouvNeu001, our innovative therapy targeting Parkinson's disease. This is a significant milestone in our mission to develop groundbreaking treatments for neurodegenerative disorders. At iRegene, we are dedicated to advancing neurodegenerative disease research and are excited about the potential impact of NouvNeu001 on the lives of those affected by Parkinson's. This approval brings us one step closer to providing a novel therapeutic option for patients in need. We extend our heartfelt gratitude to our partners, researchers, and supporters who have contributed to this achievement. #iRegene #ParkinsonsDisease #NouvNeu001 #FDAApproval #ClinicalTrials #NeurodegenerativeResearch #InnovationInHealthcare #Biotechnology

83

6 Comments